Summary by Moomoo AI
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) on 9 February 2024, with its indirect wholly owned subsidiary as a buyer, acquired 35% shareholding in Hong Kong Oriental, providing further information to potential investors and shareholders. The price and payment terms of the transaction are determined on the basis of normal commercial terms and after fair consultation. Kangfang Biological Supplement states that the vendor's investment amount (RMB185,000,000) and its carrying value (RMB 0) and its carrying value (RMB 0) and the development phase of two new drugs under the auspices of CFU were taken into account in the agreement's terms. The supplemental information does not affect the rest of the previous announcement.